Open for inclusion

A phase Ib/II, multicenter, open-label study of EGF816 in combination with INC280 in adult patients with EGFR mutated non-small cell lung cancer

Cancer type: Lung cancer

Phase: I/II

Principal Investigator: Sprauten Mette

Country: NO

Keywords: Norway, Oslo, NSCLC, EGFR mutated

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02335944?term=cinc280x2105c&rank=1